

**UNITED STATES DEPARTMENT OF COMMERCE****United States Patent and Trademark Office**Address: COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231*Ca*

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.
09/345,148	06/30/99	SEGAL	A 3378/80490

KATHLEEN M WILLIAM ESQ
BANNER & WITCOFF LTD
28 STATE STREET
BOSTON MA 02109

HM12/0619

EXAMINER

GAMBEL, P

ART UNIT	PAPER NUMBER
----------	--------------

1644

DATE MAILED:

06/19/01

Please find below and/or attached an Office communication concerning this application or proceeding.

Commissioner of Patents and Trademarks



UNITED STATES DEPARTMENT OF COMMERCE
Patent and Trademark Office
COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231

DEA/FCE-1994

09/345148

SERIAL NUMBER	FILING DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NO.

EXAMINER	
ART UNIT	PAPER NUMBER
1644	18

DATE MAILED:

Please find below a communication from the EXAMINER in charge of this application

Commissioner of Patents

Applicant's response filed 4/5/01 (Paper No. 10) is not fully responsive to the Restriction Requirement, mailed 11/27/00 (Paper No. 8). See 37 CFR 1.111.

Claims 69-70 have been added.

Applicant's election of Group I (claims 1-15, 28 and 29) and the species lipid linked CD40-specific antibody with traverse is acknowledged.

However applicant was required to elect a species from each of the following if Group I was elected.

This application contains claims directed to the following patentably distinct species of the claimed Groups I/II/III/IV/V/VI: wherein the CD40L enhanced cells or engineered CD40 ligand is/further comprises an CD40 ligand selected from the group consisting of:

- A) CD40 or
- B) CD40-specific antibody.

This application contains claims directed to the following patentably distinct species of the claimed Groups I/II/III/IV/V/VI: wherein the CD40L enhanced cells or engineered CD40 ligand is/further comprises an opsonin selected from the group consisting of:

- A) mannose binding protein or
- B) alpha chain of C3b.

This application contains claims directed to the following patentably distinct species of the claimed Groups I/II/III/IV/V/VI: wherein the CD40L enhanced cells or engineered CD40 ligand is/further comprises an opsonin selected from the group consisting of:

- A) mannose binding protein or
- B) alpha chain of C3b.

The reply filed on 9 is not fully responsive to the prior Office action because of the following omission(s) or matter(s):. Since the above-mentioned reply appears to be *bona fide*, applicant is given **ONE (1) MONTH or THIRTY (30) DAYS** from the mailing date of this notice, whichever is longer, within which to supply the omission or correction in order to avoid abandonment. **EXTENSIONS OF THIS TIME PERIOD MAY BE GRANTED UNDER 37 CFR 1.136(a).**

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Phillip Gambel whose telephone number is (703) 308-3997. The examiner can normally be reached Monday through Thursday from 7:30 am to 6:00 pm. A message may be left on the examiner's voice mail service. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Christina Chan can be reached on (703) 308-3973. Any inquiry of a general nature or relating to the status of this application should be directed to the Technology Center 1600 receptionist whose telephone number is (703) 308-0196.

Papers related to this application may be submitted to Technology Center 1600 by facsimile transmission. Papers should be faxed to Technology Center 1600 via the PTO Fax Center located in Crystal Mall 1. The faxing of such papers must conform with the notice published in the Official Gazette, 1096 OG 30 (November 15, 1989). The CM1 Fax Center telephone number is (703) 305-3014.



Phillip Gambel, PhD.
Primary Examiner
Technology Center 1600
June 18, 2001